Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Microbix Biosystems Inc. Regulatory Filings 2021

May 13, 2021

43412_rns_2021-05-12_6e72f5f4-85fc-417e-b084-e02b642c85e4.pdf

Regulatory Filings

Open in viewer

Opens in your device viewer

Ernst & Young LLP Ernst & Young Tower 100 Adelaide Street West, P.O. Box 1 Toronto, Ontario M5H 0B3

==> picture [71 x 81] intentionally omitted <==

Tel: +1 416 864 1234 Fax: +1 416 864 1174 ey.com/ca

12 May 2021

British Columbia Securities Commission Alberta Securities Commission Saskatchewan Financial Services Commission Manitoba Securities Commission Ontario Securities Commission New Brunswick Securities Commission Nova Scotia Securities Commission Prince Edward Island, Securities Division Securities Commissions of Newfoundland/Labrador

Re: Microbix Biosystems Inc. (the “Company”)

Dear Sirs / Mesdames:

We refer to the short form prospectus of the Company dated 12 May 2021 (the “Prospectus”) relating to the sale and issue of 8,333,334 Units (each unit consisting of one Common Share and one-half of one Common Share purchase warrant) of the Company.

We consent to being named and to the use, through incorporation by reference in the Prospectus, of our report dated 17 December 2020 to the shareholders of the Company on the following consolidated financial statements:

  • Consolidated statements of financial position as at 30 September 2020 and 2019; and

  • Consolidated statements of income (loss) and comprehensive income (loss), changes in shareholders’ equity and cash flows for the years ended 30 September 2020 and 2019, and a summary of significant accounting policies and other explanatory information.

We report that we have read the Prospectus and all information specifically incorporated by reference therein and have no reason to believe that there are any misrepresentations in the information contained therein that are derived from the financial statements upon which we have reported or that are within our knowledge as a result of our audit of such consolidated financial statements.

We have complied with Canadian generally accepted standards for an auditor’s consent to the use of a report of the auditor included in an offering document, which does not constitute an audit or review of the Prospectus as these terms are described in the CPA Canada Handbook – Assurance.

Yours very truly,

==> picture [116 x 45] intentionally omitted <==

A member firm of Ernst & Young Global Limited